Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adaptive BiotechnologiesADPT +2.16%65 Earnings per Share (Diluted) is $-0.41 as of Jun. 2026. GuruFocus rates ADPT with a GF Score™ of 65/100 and a GF Value™ of $11.76 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 157 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks better than 73.89% on this metric.
During the past 3 years, the average EPS without NRIGrowth Rate was 34.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 16.50% per year.
During the past 9 years, Adaptive Biotechnologies's highest 3-Year average EPS without NRI Growth Rate was 34.70% per year. The lowest was -49.90% per year. And the median was -9.55% per year.
Adaptive Biotechnologies (NAS:ADPT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Adaptive Biotechnologies Earnings per Share (Diluted) Related Terms
Adaptive Biotechnologies Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Adaptive Biotechnologies's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Earnings per Share (Diluted) Chart
ADPT vs GRAL, VCYT, RDNT: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's PE Ratio distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's PE Ratio falls into.
Adaptive Biotechnologies Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Adaptive Biotechnologies's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.41 mean?
Adaptive Biotechnologies (ADPT) has a Earnings per Share (Diluted) of $-0.41 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #41 out of 157 companies in the Medical Diagnostics & Research industry, placing it in the top 26.1%.
Is Adaptive Biotechnologies' Earnings per Share (Diluted) too high?
Adaptive Biotechnologies' current Earnings per Share (Diluted) is $-0.41. Based on the distribution chart, Adaptive Biotechnologies ranks #41 out of 157 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Adaptive Biotechnologies has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Earnings per Share (Diluted) compare to GRAL and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #41 out of 157 companies for Earnings per Share (Diluted). This puts Adaptive Biotechnologies in the upper half of its industry. The industry median Earnings per Share (Diluted) is 10.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.70, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current Earnings per Share (Diluted) is $-0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.76, compared to a current price of $25.99 — trading 121% above its estimated fair value. The current Earnings per Share (Diluted) is $-0.41. Adaptive Biotechnologies' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Earnings per Share (Diluted) is $-0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of $25.99 is trading 121% above its estimated GF Value™ of $11.76.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for ADPT:
Earnings per Share (Diluted): $-0.41
GF Value™: $11.76 vs. price of $25.99 (121% above fair value)
No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
65GF Score
Get the complete analysis for ADPT
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADPT has been successfully added to your 
